That Sergeant Bowe bergdahl, who was held in captivity for five years, has been charged with desertion and ms. Shaving before the enemy. And misbehaving before the enemy. The numbers are on the screen. You can also send us a tweet or go to facebook. And you can also send us an email. The announcement came from fort bragg yesterday from the army, outlining the charges against Sergeant Bowe bergdahl. Take a look at what they had to say. [video clip] the u. S. Army command has thoroughly reviewed the allegations surrounding Sergeant Bowe bergdahls disappearance and formally charged him on march 25, 2015 with desertion with intent to shirk important or hazardous duty and misbehavior before the enemy and has referred the case to an article 32 preliminary hearing. Host colonel daniel king the spokesman for the u. S. Army forces command then went on to talk about the potential punishment for Sergeant Bergdahl. Take a look. [video clip] colonel king there are potential punishment associated wi
JB Pharma Records Revenue Growth Of 14% To ₹896 Cr In Q1 FY24
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
Alembic Pharmaceuticals revenue up by 18% to Rs 1486 crores in Q-1 FY24
bilkulonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bilkulonline.com Daily Mail and Mail on Sunday newspapers.
Alembic Pharmaceuticals rose 1.67% to Rs 999.40 after the company s consolidated net profit jumped 12% to Rs 251 crore on 6% increase in net sales to Rs 1,280 crore in Q4 FY21 over Q4 FY20.On a consolidated basis, the company s net profit jumped 42% to Rs 1178 crore on 17% increase in net sales to Rs 5393 crore in the year ended March 2021 over the year ended March 2020.
International formulations jumped 19% Y-o-Y (year-on-year) to Rs 2,942 crore in FY21 over FY20. US Generics spurted 9% Y-o-Y to Rs 2,163 crore in FY21 over FY20. Ex-US International Formulations soared 57% Y-o-Y to Rs 779 crore in FY21.
13 ANDA s were filed in the quarter and 29 ANDA filings for the year. Research & Department (R&D) spend was reported at 12% of revenue or Rs 670 crore for the year.
Alembic Pharma Q3 standalone net up 19% at ₹277 crore
January 19, 2021
Formulations business grows 3% in international markets, 14% in domestic market Pharma player Alembic Pharmaceuticals Limited on Tuesday posted standalone net profit at ₹277 crore for the quarter ended December 31, 2020, which is about 19 per cent higher than ₹233 crore reported in the corresponding quarter last year.
The company’s standalone revenues from operations stood at ₹1,236 crore for the quarter as against ₹1,052 crore in the same period last year.
On a consolidated basis, the company posted net profit of ₹293 crore for the quarter ended December 2020, which is about 25 per cent higher than ₹234 crore reported in the corresponding quarter last year.